{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:21:11Z","timestamp":1790803271983,"version":"4.1.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100016386","name":"Conselleria de Innovaci\u00f3n, Universidades, Ciencia y Sociedad Digital, Generalitat Valenciana","doi-asserted-by":"publisher","award":["PROMETEO\/2021\/031"],"award-info":[{"award-number":["PROMETEO\/2021\/031"]}],"id":[{"id":"10.13039\/501100016386","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014440","name":"Ministerio de Ciencia, Innovaci\u00f3n y Universidades","doi-asserted-by":"publisher","award":["PID2021-126423OB-C21"],"award-info":[{"award-number":["PID2021-126423OB-C21"]}],"id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020619","name":"Universidad Miguel Hern\u00e1ndez","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100020619","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Up to 80% of patients undergoing taxanes or platinum-based chemotherapy (CT) develop a peripheral polyneuropathy (CIPN), that affects treatment compliance and quality of life (QoL). CIPN is characterized by a remarkable sensitization of peripheral nociceptive endings. We performed a proof-of-concept, double-blind, randomized, two-arms, multicenter clinical study to evaluate if protecting epidermal nociceptive endings with a topical nociceutical formulation prevented CIPN and augmented QoL during CT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Material and methods<\/jats:title>\n                    <jats:p>Participants started a daily topical application of the assigned formulation in hands (moisturizing or nociceutical). Upon appearance of neuropathic symptoms in hands or feet, they applied the creams twice daily. Diagnosis and follow-up of CIPN was performed using the CTC AE v5.0 criteria.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A cohort of 142 patients treated with taxanes and\/or platinum agents were randomly distributed into the arms. Withdrawals were similar in both arms. A lower CIPN incidence in hands was observed in the nociceutical arm (32% vs 13%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.03), while a similar number of participants developed CIPN in feet (73% vs 67%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.1). Interestingly, the nociceutical formulation increased the number of CT cycles CIPN free (6 vs 8 cycle,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.009). The Leonard Scale Questionnaire revealed that 60% of patients using the moisturizing cream reported frequently bothersome neuropathic symptoms, compared with only 39% in the nociceutical group (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0017).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Protection of nociceptive epidermal terminals with a topical nociceutical formulation reduced the incidence of CIPN in hands and increased the QoL of patients. These findings provide a solid ground for a confirmatory clinical study.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12094-025-04062-1","type":"journal-article","created":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T06:04:15Z","timestamp":1759298655000},"page":"1040-1048","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["A topical nociceutical formulation ameliorates chemotherapy-induced peripheral neuropathy: a pilot randomized clinical study"],"prefix":"10.1007","volume":"28","author":[{"given":"Sonia","family":"Servitja","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Castro-Henriques","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I\u00f1aki","family":"\u00c1lvarez-Busto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlota","family":"D\u00edez-Franco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alba","family":"Medina-Castillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Asunci\u00f3n","family":"Algarra-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"L\u00f3pez-Miranda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Lario-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Isabel","family":"Luengo-Alc\u00e1zar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Borreg\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Dav\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Gasull-Delgado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Roque-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Gonzaga-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas Manuel","family":"Poveda-Ferriols","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Severine","family":"Pascal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Mar\u00eda","family":"Mitroi-Marinescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Garc\u00eda-Escolano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asia","family":"Fern\u00e1ndez-Carvajal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clotilde","family":"Ferr\u00e1ndiz-Huertas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2973-6607","authenticated-orcid":false,"given":"Antonio","family":"Ferrer-Montiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,1]]},"reference":[{"issue":"2","key":"4062_CR1","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s40487-021-00168-y","volume":"9","author":"J Burgess","year":"2021","unstructured":"Burgess J, Ferdousi M, Gosal D, Boon C, Matsumoto K, Marshall A, et al. Chemotherapy-induced peripheral neuropathy: epidemiology, pathomechanisms and treatment. Oncol Ther. 2021;9(2):385\u2013450.","journal-title":"Oncol Ther"},{"issue":"30","key":"4062_CR2","doi-asserted-by":"publisher","first-page":"3416","DOI":"10.1200\/JCO.2014.58.8533","volume":"33","author":"DR Pachman","year":"2015","unstructured":"Pachman DR, Qin R, Seisler DK, Smith EML, Beutler AS, Ta LE, et al. Clinical course of oxaliplatin-induced neuropathy: results from the randomized phase III trial N08CB (Alliance). J Clin Oncol. 2015;33(30):3416\u201322.","journal-title":"J Clin Oncol"},{"issue":"12","key":"4062_CR3","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1016\/j.pain.2014.09.020","volume":"155","author":"M Seretny","year":"2014","unstructured":"Seretny M, Currie GL, Sena ES, Ramnarine S, Grant R, MacLeod MR, et al. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. Pain. 2014;155(12):2461\u201370.","journal-title":"Pain"},{"issue":"18","key":"4062_CR4","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1200\/JCO.2013.54.0914","volume":"32","author":"DL Hershman","year":"2014","unstructured":"Hershman DL, Lacchetti C, Dworkin RH, Lavoie Smith EM, Bleeker J, Cavaletti G, et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2014;32(18):1941\u201367.","journal-title":"J Clin Oncol"},{"issue":"1","key":"4062_CR5","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s11864-021-00926-0","volume":"23","author":"JN Mezzanotte","year":"2022","unstructured":"Mezzanotte JN, Grimm M, Shinde NV, Nolan T, Worthen-Chaudhari L, Williams NO, et al. Updates in the treatment of chemotherapy-induced peripheral neuropathy. Curr Treat Options Oncol. 2022;23(1):29\u201342.","journal-title":"Curr Treat Options Oncol"},{"key":"4062_CR6","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s10549-023-07172-y","volume":"204","author":"MK Accordino","year":"2024","unstructured":"Accordino MK, Lee S, Leu CS, Levin B, Trivedi MS, Crew KD, et al. Randomized adaptive selection trial of cryotherapy, compression therapy, and placebo to prevent taxane-induced peripheral neuropathy in patients with breast cancer. Breast Cancer Res Treat. 2024;204:49\u201359.","journal-title":"Breast Cancer Res Treat"},{"key":"4062_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2023.11.014","volume":"25","author":"JS Gewandter","year":"2024","unstructured":"Gewandter JS, Culakova E, Davis JN, Gada U, Guido JJ, Bearden JD, et al. Wireless transcutaneous electrical nerve stimulation (TENS) for chronic chemotherapy-induced peripheral neuropathy (CIPN): a proof-of-concept randomized clinical trial. J Pain. 2024;25:104431.","journal-title":"J Pain"},{"issue":"6","key":"4062_CR8","doi-asserted-by":"publisher","first-page":"e436","DOI":"10.1093\/oncolo\/oyad065","volume":"28","author":"MC Huang","year":"2023","unstructured":"Huang MC, Chang SC, Liao WL, Ke TW, Lee AL, Wang HM, et al. Acupuncture may help to prevent chemotherapy-induced peripheral neuropathy: a randomized, sham-controlled, single-blind study. Oncologist. 2023;28(6):e436\u201347.","journal-title":"Oncologist"},{"issue":"1","key":"4062_CR9","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1002\/cam4.2693","volume":"9","author":"DS Wang","year":"2020","unstructured":"Wang DS, Wang ZQ, Chen G, Peng JW, Wang W, Deng YH, et al. Phase III randomized, placebo-controlled, double-blind study of monosialotetrahexosylganglioside for the prevention of oxaliplatin-induced peripheral neurotoxicity in stage II\/III colorectal cancer. Cancer Med. 2020;9(1):151\u20139.","journal-title":"Cancer Med"},{"issue":"12","key":"4062_CR10","volume":"31","author":"B Tawfik","year":"2023","unstructured":"Tawfik B, Dayao ZR, Brown-Glaberman UA, Pankratz VS, Lafky JM, Loprinzi CL, et al. A pilot randomized, placebo-controlled, double-blind study of omega-3 fatty acids to prevent paclitaxel-associated acute pain syndrome in breast cancer patients: Alliance A22_Pilot2. Support Care Cancer. 2023;31(12):637.","journal-title":"Support Care Cancer"},{"issue":"3","key":"4062_CR11","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.pmn.2022.12.008","volume":"24","author":"DL Langley-Brady","year":"2023","unstructured":"Langley-Brady DL, Campbell RT, Maihle NJ, Barnes VA, Bratton AR, Zadinsky JK. A pilot randomized controlled trial evaluating essential oils for chemotherapy-induced peripheral neuropathy. Pain Manag Nurs. 2023;24(3):289\u201398.","journal-title":"Pain Manag Nurs"},{"issue":"3","key":"4062_CR12","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.21037\/apm-23-90","volume":"12","author":"K Cho","year":"2023","unstructured":"Cho K, Saikawa H, Hashimoto T, Katagiri H, Owada Y, Yakuwa K, et al. A randomized trial to evaluate the preventive effect of lafutidine on chemotherapy-induced peripheral neuropathy in patients treated with carboplatin and paclitaxel for lung cancer. Ann Palliat Med. 2023;12(3):1136\u201345.","journal-title":"Ann Palliat Med"},{"issue":"24","key":"4062_CR13","doi-asserted-by":"publisher","first-page":"3325","DOI":"10.1200\/JCO.20.01399","volume":"38","author":"CL Loprinzi","year":"2020","unstructured":"Loprinzi CL, Lacchetti C, Bleeker J, Cavaletti G, Chauhan C, Hertz D, et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: ASCO guideline update. J Clin Oncol. 2020;38(24):3325\u201348.","journal-title":"J Clin Oncol"},{"issue":"4","key":"4062_CR14","first-page":"351","volume":"28","author":"K Preti","year":"2024","unstructured":"Preti K, Davis ME. Chemotherapy-induced peripheral neuropathy: assessment and treatment strategies for advanced practice providers. Clin J Oncol Nurs. 2024;28(4):351\u20137.","journal-title":"Clin J Oncol Nurs"},{"key":"4062_CR15","doi-asserted-by":"publisher","first-page":"174","DOI":"10.3389\/fnmol.2017.00174","volume":"10","author":"H Starobova","year":"2017","unstructured":"Starobova H, Vetter I. Pathophysiology of chemotherapy-induced peripheral neuropathy. Front Mol Neurosci. 2017;10:174.","journal-title":"Front Mol Neurosci"},{"key":"4062_CR16","doi-asserted-by":"publisher","first-page":"5947","DOI":"10.1038\/s41598-017-05784-1","volume":"7","author":"S Imai","year":"2017","unstructured":"Imai S, Koyanagi M, Azimi Z, Nakazato Y, Matsumoto M, Ogihara T, et al. Taxanes and platinum derivatives impair Schwann cells via distinct mechanisms. Sci Rep. 2017;7:5947.","journal-title":"Sci Rep"},{"issue":"17","key":"4062_CR17","doi-asserted-by":"publisher","first-page":"3693","DOI":"10.1111\/bph.15809","volume":"179","author":"E Villalba-Riquelme","year":"2022","unstructured":"Villalba-Riquelme E, de la Torre-Mart\u00ednez R, Fern\u00e1ndez-Carvajal A, Ferrer-Montiel A. Paclitaxel in vitro reversibly sensitizes the excitability of IB4(\u2212) and IB4(+) sensory neurons from male and female rats. Br J Pharmacol. 2022;179(17):3693\u2013710.","journal-title":"Br J Pharmacol"},{"issue":"2","key":"4062_CR18","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1093\/brain\/awac273","volume":"146","author":"A Marcotti","year":"2023","unstructured":"Marcotti A, Fern\u00e1ndez-Trillo J, Gonz\u00e1lez A, Vizca\u00edno-Escoto M, Ros-Arlanz\u00f3n P, Romero L, et al. TRPA1 modulation by Sigma-1 receptor prevents oxaliplatin-induced painful peripheral neuropathy. Brain. 2023;146(2):475\u201391.","journal-title":"Brain"},{"key":"4062_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2023.1130123","volume":"16","author":"CA Baker","year":"2023","unstructured":"Baker CA, Tyagi S, Higerd-Rusli GP, Liu S, Zhao P, Dib-Hajj FB, et al. Paclitaxel effects on axonal localization and vesicular trafficking of Na(V)1.8. Front Mol Neurosci. 2023;16:1130123.","journal-title":"Front Mol Neurosci"},{"issue":"10","key":"4062_CR20","doi-asserted-by":"publisher","first-page":"4436","DOI":"10.1021\/acs.jmedchem.8b00109","volume":"61","author":"M Serafini","year":"2018","unstructured":"Serafini M, Griglio A, Aprile S, Seiti F, Travelli C, Pattarino F, et al. Targeting transient receptor potential vanilloid 1 (TRPV1) channel softly: the discovery of Passerini adducts as a topical treatment for inflammatory skin disorders. J Med Chem. 2018;61(10):4436\u201355.","journal-title":"J Med Chem"},{"issue":"1","key":"4062_CR21","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1038\/s41598-020-80725-z","volume":"11","author":"M Nikolaeva-Koleva","year":"2021","unstructured":"Nikolaeva-Koleva M, Butr\u00f3n L, Gonz\u00e1lez-Rodr\u00edguez S, Devesa I, Valente P, Serafini M, et al. A capsaicinoid-based soft drug, AG1529, for attenuating TRPV1-mediated histaminergic and inflammatory sensory neuron excitability. Sci Rep. 2021;11(1):246.","journal-title":"Sci Rep"},{"key":"4062_CR22","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/1471-2407-5-116","volume":"5","author":"GD Leonard","year":"2005","unstructured":"Leonard GD, Wright MA, Quinn MG, Fioravanti S, Harold N, Schuler B, et al. Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancer. BMC Cancer. 2005;5:116.","journal-title":"BMC Cancer"},{"key":"4062_CR23","doi-asserted-by":"publisher","first-page":"174480691771469","DOI":"10.1177\/1744806917714693","volume":"13","author":"KA Aromolaran","year":"2017","unstructured":"Aromolaran KA, Goldstein PA. Ion channels and neuronal hyperexcitability in chemotherapy-induced peripheral neuropathy; cause and effect? Mol Pain. 2017;13:1744806917714693.","journal-title":"Mol Pain"},{"key":"4062_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2024.1345811","volume":"17","author":"X Chen","year":"2024","unstructured":"Chen X, Gan Y, Au NPB, Ma C. Current understanding of the molecular mechanisms of chemotherapy-induced peripheral neuropathy. Front Mol Neurosci. 2024;17:1345811.","journal-title":"Front Mol Neurosci"},{"issue":"9 Pt B","key":"4062_CR25","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1016\/j.bbamem.2017.04.012","volume":"1859","author":"MG Ciardo","year":"2017","unstructured":"Ciardo MG, Ferrer-Montiel A. Lipids as central modulators of sensory TRP channels. Biochim Biophys Acta Biomembr. 2017;1859(9 Pt B):1615\u201328.","journal-title":"Biochim Biophys Acta Biomembr"},{"issue":"9","key":"4062_CR26","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1016\/j.bbamem.2015.03.022","volume":"1848","author":"FJ Taberner","year":"2015","unstructured":"Taberner FJ, Fern\u00e1ndez-Ballester G, Fern\u00e1ndez-Carvajal A, Ferrer-Montiel A. TRP channels interaction with lipids and its implications in disease. Biochim Biophys Acta. 2015;1848(9):1818\u201327.","journal-title":"Biochim Biophys Acta"},{"issue":"9","key":"4062_CR27","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1038\/s41594-024-01299-2","volume":"31","author":"WR Arnold","year":"2024","unstructured":"Arnold WR, Mancino A, Moss FR, Chen J, Frost A, Cheng Y. Structural basis of TRPV1 modulation by endogenous bioactive lipids. Nat Struct Mol Biol. 2024;31(9):1377\u201385.","journal-title":"Nat Struct Mol Biol"},{"issue":"11","key":"4062_CR28","doi-asserted-by":"publisher","first-page":"2787","DOI":"10.1007\/s11136-013-0379-8","volume":"22","author":"EM Lavoie Smith","year":"2013","unstructured":"Lavoie Smith EM, Barton DL, Qin R, Steen PD, Aaronso NK, Loprinzi CL. Assessing patient-reported peripheral neuropathy: the reliability and validity of the European Organization for Research and Treatment of Cancer QLQ-CIPN20 questionnaire. Qual Life Res. 2013;22(11):2787\u201399.","journal-title":"Qual Life Res"},{"issue":"2","key":"4062_CR29","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1111\/j.1085-9489.2006.00078.x","volume":"11","author":"G Cavaletti","year":"2006","unstructured":"Cavaletti G, Jann S, Pace A, Plasmati R, Siliciano G, Briani C, et al. Multi-center assessment of the Total Neuropathy Score for chemotherapy-induced peripheral neurotoxicity. J Peripher Nerv Syst. 2006;11(2):135\u201341.","journal-title":"J Peripher Nerv Syst"},{"issue":"4","key":"4062_CR30","doi-asserted-by":"publisher","first-page":"2384","DOI":"10.1007\/s13311-021-01142-2","volume":"18","author":"EH Bae","year":"2021","unstructured":"Bae EH, Greenwald MK, Schwartz AG. Chemotherapy-induced peripheral neuropathy: mechanisms and therapeutic avenues. Neurotherapeutics. 2021;18(4):2384\u201396.","journal-title":"Neurotherapeutics"},{"issue":"12","key":"4062_CR31","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1038\/nrneurol.2014.211","volume":"10","author":"M Sisignano","year":"2014","unstructured":"Sisignano M, Baron R, Scholich K, Geisslinger G. Mechanism-based treatment for chemotherapy-induced peripheral neuropathic pain. Nat Rev Neurol. 2014;10(12):694\u2013707.","journal-title":"Nat Rev Neurol"}],"updated-by":[{"DOI":"10.1007\/s12094-025-04116-4","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000}}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-025-04062-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-025-04062-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-025-04062-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T14:19:32Z","timestamp":1771510772000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-025-04062-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,1]]},"references-count":31,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["4062"],"URL":"https:\/\/doi.org\/10.1007\/s12094-025-04062-1","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,1]]},"assertion":[{"value":"18 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2025","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised: to include the contributions of author Clotilde Ferr\u00e1ndiz-Huertas and to correct the funding number.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2025","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s12094-025-04116-4","URL":"https:\/\/doi.org\/10.1007\/s12094-025-04116-4","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"CFH and MGE are the employees and shareholders of Prospera Biotech. AFC and AFM are the inventors of patent\u00a0EP3621950B1\u00a0protecting non-pungent vanilloid analogs, and shareholders and board members of Prospera Biotech.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Authors declare that this study has been approved by the appropriate ethics committee and have, therefore, been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All participants provided signed informed consent.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"This study was presented at: (1) the Spanish Medical Oncology Congress 2024; (2) the San Antonio Breast Cancer Symposium 2024; and (3) posted in MedrXiv:\n                      \n                      .","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}